行情

EYES

EYES

Second Sight Med
NASDAQ

实时行情|Nasdaq Last Sale

0.8400
-0.1097
-11.55%
盘后: 0.8299 -0.0101 -1.20% 17:19 04/03 EDT
开盘
0.8400
昨收
0.9497
最高
0.8600
最低
0.8200
成交量
21.96万
成交额
--
52周最高
9.60
52周最低
0.8200
市值
1,315.25万
市盈率(TTM)
-0.0449
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EYES价格均价为7.25,最高价位12.00,最低价为2.500。

EPS

EYES 新闻

更多
  • Company News for Apr 1, 2020
  • Zacks · 4天前
  • The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
  • Benzinga · 4天前
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 5天前
  • Second Sight to fold up the tent; shares down 49%
  • Seeking Alpha - Article · 6天前

所属板块

医疗设备、用品及经销
-0.92%
医疗设备和用品
-1.17%

热门股票

代码
价格
涨跌幅

EYES 简况

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
展开

微牛提供Second Sight Medical Products Inc(NASDAQ-EYES)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EYES股票新闻,以帮助您做出投资决策。